Initial treatment options for adults with social anxiety disorder include non drug treatment options but if the person wishes to proceed with a pharmacological intervention sertraline is an option

FP10 POM

Low dose Combisal more cost effective than Seretide

Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes as per NICE TA572

Sytron (sodium feredetate 27.5mg/5ml) oral solution sugar-free is currently unavailable with an anticipated resupply date of 4 July 2025. Clinicians should: Consider whether this particular iron salt is preferred and if deemed necessary, prescribe generically (sodium feredetate 27.5mg/5ml oral solution sugar-free), considering appropriateness of use as the available product is classified as a food supplement or consider prescribing an alternative iron salt in liquid formulation that is classified as a medicinal product. Please ensure the patient has no documented intolerance to the iron salt prescribed and advice on dose to be administered is provided to the patient/carer; and Ensure there is no intolerance to excipients of alternative product selected, note that Galfer Liquid contains milk. For other excipients see SmPC. Please see the medicine supply notification on the SPS website for full details and further management options.

Mild papulopustular rosacea is usually managed by azelaic acid 15% gel. For moderate to severe inflammatory lesions of rosacea where a topical treatment is appropriate, ivermectin 1% cream should be used instead of topical metronidazole. Systemic antibiotics are reserved for more severe disease.

For patients who have been diagnosed with head and neck cancer or undertaken a course of radiotherapy, and who require high-strength fluoride toothpaste as part of the cancer pathway, sodium fluoride dental paste sugar-free 1.1% (5000ppm) may be prescribed on a three-monthly basis by their NHS dentist or GP on the advice of the head & neck cancer, maxillofacial, or restorative dental teams. All other prescribing is discouraged.

Please see shared care guidelines for information as to when it is suitable for GP to initiate prescribing based on cardiology advice

Please see shared care guidelines for information as to when it is suitable for GP to initiate prescribing based on cardiology advice

Specialist initiated or advised only

Specialist initiated or advised only

Specialist initiated or advised only

Please see shared care guidelines for information as to when it is suitable for GP to initiate prescribing based on cardiology advice

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

Simbrinza – a combination of brinzolamide and brimonidine– is accepted onto the formulary for decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.

Administered OD (night/evening)

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

Sevelamer carbonate (available as generic tablet) is the preferred salt

Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.

Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.

The routine commissioning of Sativex is accepted in Cornwall for the treatment of spasticity due to multiple sclerosis only when specific criteria are met.

Prescribing to remain within secondary care specialist weight management service as per NICE TA 875

Prescribing to remain within secondary care specialist weight management service as per NICE TA 875

Prescribing to remain within secondary care specialist weight management service as per NICE TA 875

Prescribing to remain within secondary care specialist weight management service as per NICE TA 875

Prescribing to remain within secondary care specialist weight management service as per NICE TA 875

To be prescribed via specialist weight management service only

NICE TA358 Tolvaptan is recommended as an option for the treatment of autosomal dominant polycystic kidney disease in adults when specified criteria are met (October 2015) Hyponatraemia secondary to SIADH in patients requiring cancer chemotherapy. Commissioned by NHS England

NICE TA358 Tolvaptan is recommended as an option for the treatment of autosomal dominant polycystic kidney disease in adults when specified criteria are met (October 2015) Hyponatraemia secondary to SIADH in patients requiring cancer chemotherapy. Commissioned by NHS England

Do not prescribe